Applied Therapeutics stock surges amid market gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 Jan 26
Source: Benzinga
Applied Therapeutics Inc's stock price surged by 38.14% in pre-market trading as it crossed above the 5-day SMA, reflecting strong investor interest.
The significant price movement comes amid positive market conditions, with the Nasdaq-100 and S&P 500 both showing gains of 0.77% and 0.36%, respectively. This broad market strength appears to have contributed to the upward momentum in APLT's stock price.
Investors are optimistic about the company's future prospects, which may be bolstered by the overall market performance, indicating a favorable environment for growth.
Analyst Views on APLT
Wall Street analysts forecast APLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLT is 0.25 USD with a low forecast of 0.25 USD and a high forecast of 0.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
0 Buy
4 Hold
0 Sell
Hold
Current: 0.093
Low
0.25
Averages
0.25
High
0.25
Current: 0.093
Low
0.25
Averages
0.25
High
0.25
About APLT
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
